Biomarkers of cell death applicable to early clinical trials.

[1]  R. Plummer,et al.  A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Soria,et al.  Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Herbst,et al.  Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours , 2011, British Journal of Cancer.

[4]  T. Seto,et al.  Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors , 2011, Archives of drug information.

[5]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Berger,et al.  Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. , 2011, Neoplasia.

[7]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[8]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Xiaoyuan Chen,et al.  Positron emission tomography imaging of cancer biology: current status and future prospects. , 2011, Seminars in oncology.

[10]  J. Radford,et al.  Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma , 2011, British Journal of Cancer.

[11]  W. Frankel,et al.  Modulation of Genetic and Epigenetic Biomarkers of Colorectal Cancer in Humans by Black Raspberries: A Phase I Pilot Study , 2010, Clinical Cancer Research.

[12]  Alan Ashworth,et al.  Synthetic lethal approaches to breast cancer therapy , 2010, Nature Reviews Clinical Oncology.

[13]  D. Andrews,et al.  Drugs targeting Bcl-2 family members as an emerging strategy in cancer , 2010, Expert Reviews in Molecular Medicine.

[14]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[15]  W. Plunkett,et al.  Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Lillian L. Siu,et al.  Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma , 2010, Clinical Cancer Research.

[17]  M. Alunni-Fabbroni,et al.  Circulating tumour cells in clinical practice: Methods of detection and possible characterization. , 2010, Methods.

[18]  W. Greenhalf,et al.  Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer , 2010, British Journal of Cancer.

[19]  G. Doyle,et al.  Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer , 2009, Journal of oncology.

[20]  Caroline Dive,et al.  Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy , 2010 .

[21]  M. Schluchter,et al.  Phase II study of bryostatin 1 and vincristine for aggressive non‐Hodgkin lymphoma relapsing after an autologous stem cell transplant , 2009, American journal of hematology.

[22]  L. Fazal,et al.  Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283 , 2009, Cell cycle.

[23]  J. Litz,et al.  Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737 , 2009, Molecular Cancer Therapeutics.

[24]  Stephen J. Morris,et al.  Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  David E Reichert,et al.  [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98. , 2009, Organic & biomolecular chemistry.

[26]  S. Kaye,et al.  From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs , 2009, Clinical pharmacology and therapeutics.

[27]  M. Ratain,et al.  Biomarkers in Early Cancer Drug Development: Limited Utility , 2009, Clinical pharmacology and therapeutics.

[28]  B. Cheson,et al.  Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. , 2009, Blood.

[29]  T. Ward,et al.  Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer , 2008, Clinical Cancer Research.

[30]  E. D. de Vries,et al.  Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. , 2008, Neoplasia.

[31]  F. Blankenberg,et al.  Monitoring of treatment-induced apoptosis in oncology with PET and SPECT. , 2008, Current pharmaceutical design.

[32]  J Cummings,et al.  Biomarkers of apoptosis , 2008, British Journal of Cancer.

[33]  V. Heinemann,et al.  Clinical Relevance of Circulating Nucleosomes in Cancer , 2008, Annals of the New York Academy of Sciences.

[34]  C. Boni,et al.  Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer , 2008, Breast Cancer Research and Treatment.

[35]  K. Simpson,et al.  Optimisation of circulating biomarkers of cell death for routine clinical use. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  T. Ward,et al.  Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity , 2008, Molecular Cancer Therapeutics.

[37]  P. Pandolfi,et al.  Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes , 2008, Clinical Cancer Research.

[38]  Robert Brown,et al.  A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[39]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[40]  J Cummings,et al.  Biomarker method validation in anticancer drug development , 2008, British journal of pharmacology.

[41]  Jeffrey W. Clark,et al.  Trends in the Use and Role of Biomarkers in Phase I Oncology Trials , 2007, Clinical Cancer Research.

[42]  S. Linder,et al.  Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy , 2007, Clinical Cancer Research.

[43]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[44]  G. Jayson,et al.  Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP , 2006, British Journal of Cancer.

[45]  R. Pazdur,et al.  United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy , 2006, Clinical Cancer Research.

[46]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 , 2005, Cell Death and Differentiation.

[47]  M. Duffy,et al.  Predictive markers in breast and other cancers: a review. , 2005, Clinical chemistry.

[48]  M. Ranson,et al.  Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP , 2005, British Journal of Cancer.

[49]  K. Pienta,et al.  Apoptosis of circulating tumor cells in prostate cancer patients , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[50]  D. Vaux,et al.  Alterations in the apoptotic machinery and their potential role in anticancer drug resistance , 2003, Oncogene.

[51]  M. Dowsett,et al.  Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  M. Untch,et al.  Nucleosomes in Serum as a Marker for Cell Death , 2001, Clinical chemistry and laboratory medicine.

[53]  E. Kubista,et al.  Circulating breast cancer cells are frequently apoptotic. , 2001, The American journal of pathology.

[54]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[55]  W. Symmans,et al.  Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[57]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[58]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[59]  J. Hickman,et al.  Drug-target interactions: only the first step in the commitment to a programmed cell death? , 1991, British Journal of Cancer.

[60]  Stephen J. Morris,et al.  XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML , 2010, Apoptosis.

[61]  Paul Workman,et al.  Pharmacodynamic biomarkers for molecular cancer therapeutics. , 2007, Advances in cancer research.

[62]  F. Blankenberg,et al.  99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. , 2005, Methods in molecular medicine.

[63]  A. Wyllie,et al.  Cellular events in the adrenal cortex following ACTH deprivation. , 1972, The Journal of pathology.